Real-world experience and prognostic factors in ovarian carcinosarcoma: a single-center retrospective study from China
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Ovarian carcinosarcomas (OCS) are rare. This study identified age, tumor size, Ki-67, and ascites as potential prognostic factors for OCS. Patients with homologous recombination deficiency (HRD) may benefit from PARP inhibitors.
Area Of Science
- Oncology
- Gynecologic Oncology
- Cancer Research
Background
- Ovarian carcinosarcomas (OCS) are rare and aggressive tumors.
- Limited data exists due to low incidence, hindering understanding of prognostic factors and optimal treatment strategies.
Purpose Of The Study
- To investigate potential prognostic factors for ovarian carcinosarcomas.
- To explore effective treatment strategies for patients with OCS.
Main Methods
- Retrospective analysis of 26 OCS patients diagnosed between March 2012 and October 2023.
- Kaplan-Meier analysis was used to assess progression-free survival (PFS).
- Genetic testing was performed on a subset of patients.
Main Results
- Median PFS for all patients was 17.53 months.
- Factors such as younger age, smaller tumor diameter, lower ascites volume, and lower Ki-67 index showed a trend towards better prognosis.
- Four out of five patients with HRD-positive status treated with PARP inhibitors (PARPi) achieved a median PFS of 22.68 months.
Conclusions
- Age, tumor diameter, Ki-67 index, and ascites volume may serve as prognostic indicators for OCS.
- Homologous recombination deficiency (HRD)-positive status, potentially including BRCA mutations, suggests a benefit from PARP inhibitor therapy.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.